Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Corticosteroids in Japanese Subjects with Acute GVHD
NCT03497273Phase 1Completed
- Sponsor
- Incyte
- Start
- Mar 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events at 12 months. Started Mar 2018; status: completed.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03497273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497273.